The serum levels of dihydroneopterin (NH2), soluble interleukin -6 receptor (sIL-6R), soluble tumor necrosis factor receptor (sTNF-R) type I and type II were measured in 18 patients with major depression before and after drug treatment and in age-and gender-matched healthy controls. The NH2 and sTNF-R type II levels were significantly higher both in untreated a nd treated patients when compared to the controls. The sTNF-R type I levels were significantly lower in untreated depressed patients than the controls and significantly increased after drug treatment when compared to those prior to treatment.
Introduction
Currently, the mechanisms which underlie the interaction between the brain and the immune system are an area of widespread interest. Among mental disorders, major depression has been paid much attention as this condition may modifY immune function and effect susceptibility to physical illness. In fact, abnormal levels of a number of immune markers such as neopterin, cytokines or soluble cytokine receptors have been reported in major depression (1) (2) (3) (4) (5) (6) (7) (8) (9) . None of these previous studies, however, addressed the levels of dihydroneopte rin (NH2) or soluble tumor necro- § Author to whom correspondence should be addressed. sis factor receptor (sTNG-R) in major depression . We examined various immune markers, that is, NH2, soluble interleukin -6 receptor (sIL-6R) and sTNF-R type I and type II, in patients exhibiting major depression before and after treatment and in age-and gender-matched healthy controls.
Material and Methods
All patients and normal controls gave informed consent prior to participating in the study. None of participants had a history of drug dependence, alcohol abuse, other mental disorders or physical illness such as cancer, chronic infection, allergic diseases or any other conditions known to affect the immune system. Eighteen patients who met the DSM -IV criteria for major depressive disorder ( 10) (mean age ±SD: 42.6± 15.1, range 22.4-70.1, male: female = 11:7) and 18 age-and gendermatched controls (mean age ±SD: 42.9± 13.4, range 2S.4-68.S, male: female = 11 .7) participated in this study . Patients were also required to be free of any drug for at least 14 days before inclusion in this study. All patients were treated with antidepressants, benzodiazepines, and/ or major tranquilizers for 8 weeks. Blood samples were obtained between 10 a.m. and 2 p.m. Separated serum samples were immeqately frozen and stored at -70 n e until use . Blood samples were obtained before and after drug treatment. The serum levels mentioned below were measured by enzyme-linked immunosoluble assay (ELISA) kits . NH2 ( IBL) was quantified b y the competitive method and sIL-6R (Medgenix), sTNF-R t ype I (Medgenix) and sTNF-R type II (Medgenix) were measure d by the sandwich method. Each measurement was performed in duplicate or triplicate and the intra-assay reliability was less than 10%. The 17 -item version of the Hamilton rating scale of depression (HRS-DI7 ) was used tor evaluating depressive symptoms ( 11) and the main symptoms were assessed by the S-item , ·ersion of HRS-D (HRS-DS). The reliability among the raters for HRS-DI7 was 0.96 (an analysis of variance intra-class correlation coefficient) ( 12 ) . Paired t-test was used for statistical analysis of the serum levels between healthy controls and untreated depressed patients and between untreated and treated patients. Age-and gender-covariated multiple regression analysis was used for statistical evaluation of the relationships between the serum levels of NH2 and soluble cytokine receptors and the score of HRS-D in untreated depressed patients .
Results and Discussion
A significant improvement III depressive symptoms was achieved by drug treatment ( HRS-D 17 scores pretreatment vs. posttreatment: mean ± SD : 24.4±6 .0 vs. S .S±6.6; paired t=9.80; df=17; P < 0 .0001). Table I shows the concentrations of NH2 and soluble cyrokine receptors in patients and controls. Serum NH2 and sTNF-R type II levels In untreated patients with major depression were higher when compared to those in normal controls ( NH2 : paired t= S .OO; df= 17; P < O.OOOS, sTNF-R type II: paired t = 3 .33; df = 16; P < O.OS) and were not influenced b y treatment. The plasma total neopterin levels in major depression was reported to show similar increase both before and after treatment (6) . Sustained high serum NH2 and sTNF-R type II levels after treatment were possibly induced by the medication. T he levels of NH2 and sTNF-R type II during off· drug and remission are required to be examined.
Serum sTNF-R type I levels of depressed patients before treatment were significantly lower than those of controls ( paired t=3.93 ; df=17; p< O.OOS), and the medication caused significant increase in this levels ( paired t = 2.90; df = 17; P < 0 .01 ). This findings suggest that serum sTNF-R type I levels can be a state marker of major depression.
Serum sIL-6R levels did not differ among the group o f normal controls, untreated and treated patients although plasma concentration of sIL-6R was reported to be significantly higher in patients with major depression than in healthy controls ( 3, S).
There were no correlations between the concentrations of NH2, sIL-6R, sTNF-R type! or sTNF -R typeII and the total score of HRS-D 17 or HRS-DS in patients with major depression prior t o treatment. With regard to each item of HRS-D17 in untreated patients, there was a significant positive correlation between serum NH 2 concentrations and genital symptom (13 = 0.551; 
